Drugs and patents in ATC class V06

Last updated: August 1, 2026

V06, the WHO ATC class for general nutrients, covers nutritional products rather than a single therapeutic molecule. The class includes low-calorie products, protein preparations, amino acids, and other nutrients used in clinical nutrition, metabolic disorders, malnutrition, and parenteral support. Market competition is driven more by formulation technology, regulatory classification, hospital contracts, manufacturing controls, and distribution than by long-lived composition-of-matter patents.[1]

The patent landscape is fragmented. Core nutrient molecules such as amino acids, glucose, electrolytes, and vitamins are generally off-patent. Commercial protection instead concentrates on dosage forms, multi-nutrient combinations, stability systems, manufacturing processes, specialized pediatric or disease-specific nutrition, and delivery devices. Most V06 products do not receive the same market exclusivity structure as conventional small-molecule drugs.

What products are included in ATC Class V06?

V06 is divided into four principal groups under the WHO Anatomical Therapeutic Chemical system.[1]

ATC subgroup	Product category	Typical products and applications
V06AA	Low-calorie products	Reduced-calorie oral nutrition and dietary products
V06B	Proteins	Protein supplements, hydrolyzed proteins, clinical nutrition preparations
V06C	Amino acids	Oral or parenteral amino-acid solutions, condition-specific mixtures
V06D	Other nutrients	Carbohydrates, lipids, vitamins, minerals, trace elements, and combined nutrient preparations

The class overlaps commercially with enteral nutrition, parenteral nutrition, medical foods, oral nutritional supplements, infant nutrition, sports nutrition, and hospital compounding. Product classification can vary by jurisdiction. A formulation may be regulated as a drug, medical food, food, dietary supplement, or medical device depending on its composition, claims, route of administration, and intended population.

How large is the V06 general nutrients market?

The V06 market is best analyzed as several adjacent markets rather than as one global product category.

Hospital and clinical nutrition

Hospital nutrition is the most patent-relevant segment because products often require validated sterile manufacturing, controlled osmolality, compatibility testing, and specialized packaging. Demand comes from intensive care, oncology, surgery, renal disease, prematurity, malabsorption, and home parenteral nutrition.

Key suppliers include:

Fresenius Kabi
Baxter
B. Braun
Nestlé Health Science
Abbott
Danone, through specialized nutrition businesses
Nutricia
Kate Farms
Reckitt, through specialized nutrition brands in selected markets

Parenteral nutrition products are often sold through hospital tenders and distributor contracts. Manufacturing capacity, quality systems, and supply reliability can be more difficult for a new entrant to replicate than the nutrient composition itself.

Oral nutritional supplements

This segment includes high-protein drinks, powders, condition-specific formulas, and pediatric products. Abbott’s Ensure and PediaSure, Nestlé’s Boost and specialized nutrition products, and Danone/Nutricia’s medical nutrition portfolio illustrate the commercial importance of brand, clinical evidence, physician recommendation, and reimbursement access.

Patents may protect flavor systems, protein hydrolysates, emulsions, micronutrient combinations, packaging, or disease-specific use claims. Trademark and trade-secret protection frequently carry more commercial weight than patents for mature products.

Infant and pediatric nutrition

Pediatric and infant products have higher technical and regulatory barriers because manufacturers must address nutrient composition, tolerability, allergen control, microbiological safety, and age-specific requirements. Patent strategies may cover protein hydrolysis, prebiotic combinations, lipid structures, oligosaccharides, probiotics, and preparation methods.

The commercial risk profile differs from adult supplements. Regulatory review, pediatric clinical data, physician adoption, and safety reputation can restrict substitution even where patent protection is limited.

What patents protect V06 general nutrient products?

V06 patent protection generally falls into six categories.

Patent category	Typical protected subject matter	Commercial importance
Composition patents	Specific nutrient ratios, lipid structures, protein hydrolysates, oligosaccharide combinations	High when the formula has a differentiated clinical or nutritional profile
Formulation patents	Emulsions, suspensions, powders, reconstitution systems, pH control, osmolality, and stability	High for sterile and shelf-stable products
Method-of-use patents	Nutrition for prematurity, renal disease, sarcopenia, cancer cachexia, malabsorption, or metabolic disorders	Variable; enforceability depends on labeling and clinical use
Manufacturing patents	Mixing, sterilization, drying, encapsulation, filtration, and aseptic filling	High where process replication is difficult to detect
Packaging and delivery patents	Multi-chamber bags, vial systems, dosing systems, enteral connectors, and administration kits	Relevant in hospital and home-care channels
Microbiome and bioactive patents	Probiotic strains, prebiotics, human milk oligosaccharides, peptides, and bioactive combinations	Increasingly important in pediatric and specialty nutrition

Core nutrients do not normally provide meaningful new-molecule patent protection. The commercial value lies in the combination and the ability to demonstrate a reproducible nutritional, clinical, stability, or administration advantage.

How many patents cover V06 products?

There is no single authoritative patent count for ATC V06. ATC classification identifies therapeutic or nutritional use, not a unified patent family. A patent search can produce very different counts depending on whether it includes:

Active and expired patents
Patent applications or only granted patents
National filings or worldwide families
Food, supplement, medical-food, and device patents
Manufacturing and packaging claims
Patents assigned to suppliers rather than finished-product manufacturers

A product-level search typically produces a narrower and more commercially useful result than a class-level search. The relevant patent family may be assigned to a parent company, a subsidiary, a university, an ingredient supplier, or a contract manufacturer.

When does V06 general nutrient exclusivity expire?

V06 products do not share a common exclusivity date. Expiration depends on the specific patent family, filing date, patent-term adjustments, patent-term extensions, terminal disclaimers, and national law.

For a U.S. utility patent filed on or after June 8, 1995, the standard term is generally 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and other statutory rules.[2] Patent-term extension under 35 U.S.C. § 156 is primarily associated with regulated drugs and may not apply to products regulated as foods, dietary supplements, or medical foods.[3]

Protection mechanism	Typical relevance to V06	Timing implication
Composition patent	Limited to novel nutrient combinations or structures	Usually expires 20 years from the applicable filing date
Formulation patent	Common for complex nutritional products	May expire later than an earlier composition patent
Manufacturing patent	Common for sterile or powder products	Can remain relevant after product patents expire
Method-of-use patent	Relevant for disease-specific nutrition	Depends on claim scope and labeling
Trade secret	Common for process parameters and flavor systems	No fixed expiration while secrecy is maintained
Trademark	Important for branded nutrition	Renewable indefinitely if maintained and used
Regulatory exclusivity	Product-specific and jurisdiction-dependent	Often shorter or different from patent term

The FDA Orange Book generally does not provide a complete listing system for medical foods, dietary supplements, or ordinary nutritional products. Products approved as drugs may have Orange Book entries, but many V06 products fall outside that framework.[4]

What is the FDA regulatory status of V06 products?

FDA status depends on product claims and intended use.

Medical foods

Medical foods are formulated for the dietary management of a disease or condition with distinctive nutritional requirements. They are used under physician supervision and are not treated as conventional drugs for FDA premarket approval purposes.[5] Medical-food manufacturers remain subject to applicable labeling, manufacturing, safety, and adulteration requirements.

Dietary supplements

Dietary supplements are regulated under the Federal Food, Drug, and Cosmetic Act as amended by the Dietary Supplement Health and Education Act. They generally do not require premarket approval, although manufacturers remain responsible for safety and lawful labeling.[6]

Conventional foods and infant formulas

Infant formulas are subject to specific statutory and regulatory requirements, including nutrient composition, manufacturing, quality control, and notification obligations. The regulatory burden is materially higher than for ordinary food products.[7]

Drugs and parenteral nutrition

Injectable nutrient products, including certain amino-acid solutions and parenteral nutrition products, may be regulated as drugs. They require drug manufacturing controls and may be subject to abbreviated or full approval pathways depending on the product and reference standard.

What is the Orange Book status of V06 products?

Most V06 products have no Orange Book listing because they are not approved as drugs. The Orange Book identifies approved drug products and associated patents and exclusivity information under FDA rules.[4]

Products that may appear in or interact with the drug approval system include:

Injectable amino-acid solutions
Certain electrolyte or nutrient injections
Drug products containing nutritional ingredients with therapeutic claims
Combination products regulated as drugs
Products approved through abbreviated applications where a listed reference product exists

A lack of an Orange Book listing does not mean that a product has no patent protection. Formulation, manufacturing, packaging, and use patents may remain enforceable outside the Orange Book system.

What generic entry risks exist for V06 products?

Generic substitution risk is highest for standardized injectable nutrient products and lowest for differentiated pediatric, specialty, and device-linked formulas.

High substitution risk

Basic amino-acid solutions
Standard dextrose solutions
Common electrolyte preparations
Simple vitamin or mineral formulations
Commodity protein powders

These products have established ingredients, mature manufacturing processes, and limited brand differentiation.

Moderate substitution risk

Multi-chamber parenteral nutrition bags
Specialized renal or hepatic formulas
Hydrolyzed protein products
Condition-specific oral nutrition
Shelf-stable emulsions and reconstitution systems

Entry depends on formulation equivalence, stability, manufacturing validation, clinical evidence, and procurement access.

Lower near-term substitution risk

Pediatric formulas with proprietary protein or oligosaccharide systems
Products supported by disease-specific clinical data
Complex lipid or emulsion systems
Products integrated with administration devices
Formulas protected by active formulation and manufacturing patents

The main entry barrier is often regulatory and technical equivalence rather than the absence of an off-patent ingredient.

Which companies are challenging V06 incumbents?

Competitive pressure comes from several groups:

Generic injectable manufacturers, including established hospital-drug companies.
Contract manufacturers that can produce powders, emulsions, or sterile solutions.
Specialty-nutrition companies targeting pediatric, oncology, renal, and metabolic indications.
Ingredient suppliers developing proteins, lipids, prebiotics, probiotics, and oligosaccharides.
Consumer-health companies entering high-protein and disease-adjacent nutrition.

Competition is more fragmented than in conventional prescription drugs. No single company controls the entire V06 class. Abbott, Nestlé, Danone/Nutricia, Fresenius Kabi, Baxter, and B. Braun have strong positions in different segments, while smaller companies compete through specialized formulas and clinical positioning.

What patent litigation affects V06 general nutrients?

V06 litigation generally involves formulation patents, trade dress, trademarks, regulatory status, false advertising, or contract disputes rather than classic Paragraph IV litigation.

Paragraph IV challenges

Paragraph IV litigation under the Hatch-Waxman Act applies to patents listed for approved drugs in the Orange Book.[8] It is therefore relevant mainly to V06 products regulated as approved drugs, particularly certain injectable nutrient products. It is usually not the principal litigation route for medical foods, dietary supplements, or conventional nutrition products.

Common dispute theories

Infringement of formulation or composition claims
Misappropriation of manufacturing know-how
False or misleading comparative nutrition claims
Trademark and trade-dress infringement
Contract disputes involving hospital tenders
Regulatory-status disputes over drug, food, or medical-food classification
Patent ownership disputes involving universities and ingredient suppliers

Public litigation volume is lower than in major small-molecule pharmaceutical categories. That does not indicate weak protection. Manufacturing and formulation patents may have substantial value but remain difficult to enforce because the relevant process steps are not visible in the final product.

How strong is the V06 patent estate?

The patent estate is strongest where a product combines a defensible formulation with clinical evidence and difficult manufacturing.

Estate characteristic	Strength assessment
Basic nutrient ingredient	Weak
Novel nutrient combination	Moderate to strong
Complex emulsion or hydrolysate	Moderate to strong
Disease-specific clinical use	Moderate, depending on claim scope
Sterile manufacturing process	Strong if difficult to design around
Proprietary delivery system	Strong when integrated with the product
Flavor or sensory profile	Usually better protected by trade secret and brand
Pediatric or infant formula platform	Moderate to strong, with high regulatory barriers
Consumer supplement formula	Often weak patent protection, strong brand dependence

Freedom-to-operate analysis should examine continuation applications, divisional patents, foreign counterparts, supplier-owned patents, and process claims. A single expired composition patent does not establish freedom to operate if later formulation or manufacturing patents remain active.

What licensing deals shape the V06 market?

Licensing is common at the ingredient and platform level. Relevant transactions may involve:

Human milk oligosaccharides
Probiotic strains
Specialty lipids
Novel proteins and peptides
Prebiotic systems
Encapsulation and delivery technologies
University-developed nutrition formulations
Contract manufacturing and regional commercialization rights

Licensing arrangements can create barriers even where the finished product has no strong patent estate. A supplier may control the only scalable source of a bioactive ingredient, proprietary strain, or specialized lipid. Commercial diligence must therefore review supply agreements, field-of-use restrictions, territorial rights, minimum purchase obligations, and change-of-control provisions.

How does V06 compare with conventional pharmaceutical patent markets?

Factor	V06 general nutrients	Conventional pharmaceuticals
Core active ingredient protection	Usually limited	Often central
Orange Book relevance	Limited	Central for approved drugs
Paragraph IV litigation	Selective	Common
Formulation protection	Important	Important but secondary in many cases
Manufacturing barriers	Often decisive	Important for biologics and complex products
Brand value	High in consumer and pediatric nutrition	High but often constrained by generic substitution
Regulatory exclusivity	Fragmented	More standardized
Reimbursement	Hospital contracts, insurance, consumer pay	Prescription and payer systems
Trade-secret value	High	High for complex manufacturing
Generic entry	Product- and channel-specific	More predictable for simple small molecules

What geographic coverage matters for V06 patents?

Patent protection is territorial. A U.S. patent does not prevent manufacture or sale in Europe, China, Japan, or other markets unless corresponding rights exist.

Key jurisdictions include:

United States, because of hospital purchasing power and FDA regulation
European Union, where European patent validation and unitary patent strategies may matter
China, because of manufacturing scale and growing nutrition demand
Japan, because of aging-related nutrition and specialized clinical products
South Korea and Australia, which have developed clinical-nutrition markets
Brazil, India, and Southeast Asia, where local manufacturing and regulatory classification can affect entry

Patent owners must also consider exhaustion, parallel trade, local food and drug rules, compulsory licensing rules, and the practical enforceability of process patents.

What revenue exposure does patent expiry create?

Patent expiry usually has a smaller immediate revenue effect for V06 products than for blockbuster medicines. Revenue erosion depends on the product’s channel.

Hospital injectables can face rapid price pressure after technically equivalent entrants qualify.
Consumer oral nutrition products may retain pricing through brand loyalty, physician recommendation, and flavor differentiation.
Pediatric and infant products may retain share because switching requires clinical confidence and regulatory compliance.
Specialty formulas may remain protected by manufacturing complexity and limited capacity.
Commodity nutrient products are exposed to procurement-driven price competition regardless of patent status.

The largest commercial risk arises when a branded product relies on one formulation patent and has limited clinical or brand differentiation. The lowest risk arises when the product has multiple independent barriers, including regulatory status, clinical evidence, supplier control, manufacturing complexity, and strong distribution.

Key Takeaways

V06 covers general nutrients, including proteins, amino acids, low-calorie products, and other clinical nutrition products.
The class has no single market, patent count, or exclusivity date.
Core nutrients are largely mature and off-patent.
Formulation, manufacturing, delivery, pediatric, and disease-specific use patents provide most of the relevant protection.
Orange Book and Paragraph IV frameworks apply mainly to V06 products regulated as approved drugs.
Medical foods, dietary supplements, and conventional nutrition products usually fall outside the standard Orange Book system.
Hospital injectables face the clearest generic-entry risk.
Pediatric, specialty, and complex sterile products have stronger regulatory and manufacturing barriers.
Trade secrets, trademarks, supply agreements, clinical data, and procurement access can be as important as patents.
Geographic freedom to operate requires review of national patent families and local regulatory classifications.

FAQs About V06 General Nutrients Patents and Market Entry

Are amino acids in ATC V06 still patentable?

The basic amino acids are generally mature and off-patent. Patent protection may still apply to novel ratios, stereochemical forms, combinations, delivery systems, manufacturing processes, or disease-specific uses.

Do medical foods receive FDA drug exclusivity?

Medical foods generally do not receive conventional FDA drug approval exclusivity. Their protection may instead arise from formulation patents, trademarks, trade secrets, regulatory compliance, clinical data, and distribution relationships.[5]

Can a generic manufacturer copy a patented nutritional formula?

A manufacturer may not copy valid, enforceable patent claims. It may attempt to design around the claims by changing nutrient ratios, excipients, processing conditions, packaging, or delivery systems.

Are parenteral nutrition products subject to Paragraph IV litigation?

They can be, but only when the product is an approved drug with relevant Orange Book-listed patents. Many nutritional products are not regulated through that pathway.[4][8]

Which V06 products have the strongest barriers to entry?

Complex sterile parenteral nutrition, pediatric formulas, hydrolyzed-protein systems, proprietary lipid emulsions, and products using controlled bioactive ingredients generally have stronger barriers than basic amino-acid, glucose, electrolyte, or protein products.

References

World Health Organization Collaborating Centre for Drug Statistics Methodology. (2024). ATC/DDD index: V06 General nutrients. https://www.whocc.no/atc_ddd_index/
United States Patent and Trademark Office. (2024). Patent term calculator. https://www.uspto.gov/patents/laws/patent-term-calculator
United States Code. (2024). 35 U.S.C. § 156: Extension of patent term. https://uscode.house.gov/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Food and Drug Administration. (2024). Medical foods guidance documents and regulatory information. https://www.fda.gov/food/food-labeling-nutrition/medical-foods
U.S. Food and Drug Administration. (2024). Dietary supplements. https://www.fda.gov/food/dietary-supplements
U.S. Food and Drug Administration. (2024). Infant formula guidance and regulatory information. https://www.fda.gov/food/people-risk-foodborne-illness/infant-formula
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submissions

Drugs in ATC Class V06

Subclasses in ATC: V06 - GENERAL NUTRIENTS

V06 General Nutrients Market Dynamics and Patent Landscape